Towards understandings of serine/arginine-rich splicing factors.
10.1016/j.apsb.2023.05.022
- Author:
Dianyang LI
1
;
Wenying YU
2
;
Maode LAI
1
Author Information
1. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
2. State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Publication Type:Review
- Keywords:
Alternative splicing;
Autoimmune diseases;
Cancer therapy;
RNA metabolism;
Small molecule inhibitor;
Tauopathy
- From:
Acta Pharmaceutica Sinica B
2023;13(8):3181-3207
- CountryChina
- Language:English
-
Abstract:
Serine/arginine-rich splicing factors (SRSFs) refer to twelve RNA-binding proteins which regulate splice site recognition and spliceosome assembly during precursor messenger RNA splicing. SRSFs also participate in other RNA metabolic events, such as transcription, translation and nonsense-mediated decay, during their shuttling between nucleus and cytoplasm, making them indispensable for genome diversity and cellular activity. Of note, aberrant SRSF expression and/or mutations elicit fallacies in gene splicing, leading to the generation of pathogenic gene and protein isoforms, which highlights the therapeutic potential of targeting SRSF to treat diseases. In this review, we updated current understanding of SRSF structures and functions in RNA metabolism. Next, we analyzed SRSF-induced aberrant gene expression and their pathogenic outcomes in cancers and non-tumor diseases. The development of some well-characterized SRSF inhibitors was discussed in detail. We hope this review will contribute to future studies of SRSF functions and drug development targeting SRSFs.
